A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infection
The effective protective HIV vaccine should elicit either protective antibodies or effective T cell response, or both. To improve the efficacy of HIV-1 vaccines, HLA polymorphism and HIV-1 diversity are 2 key factors to be considered for vaccine development. In this study, we expressed a recombinant...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-06-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2017.1281488 |
_version_ | 1797674544852369408 |
---|---|
author | Yi Yang Qing Zhu Weilai Sun Jingjing Guo Xiuzhe Ning Qiao Li Yan Guo Junfeng Li Zhihua Kou Yusen Zhou |
author_facet | Yi Yang Qing Zhu Weilai Sun Jingjing Guo Xiuzhe Ning Qiao Li Yan Guo Junfeng Li Zhihua Kou Yusen Zhou |
author_sort | Yi Yang |
collection | DOAJ |
description | The effective protective HIV vaccine should elicit either protective antibodies or effective T cell response, or both. To improve the efficacy of HIV-1 vaccines, HLA polymorphism and HIV-1 diversity are 2 key factors to be considered for vaccine development. In this study, we expressed a recombinant multi-epitope protein MEP1 which has the same amino acid sequence as a DNA vaccine for Chinese population in our previous report. We found that MEP1 alone could elicit moderate levels of humoral and cellular immune responses, but these responses could not provide protection from challenge with a recombinant virus rTTV-lucgag, which expresses Gag of HIV-1 CRF_07BC. Nevertheless, when MEP1 was immunized with aluminum adjuvant, both humoral and cellular immune responses were significantly increased, and they were protective against virus infection; meanwhile, MEP1 with aluminum not only elicited early (10 d post immunization) but also a long-term (at least 44 weeks post immunization) immune responses in BALB/c mice. These results suggested that MEP1 has the potential to be developed as an effective vaccine candidate, and that suitable adjuvant is necessary for this protein to generate protective immune responses. |
first_indexed | 2024-03-11T22:00:35Z |
format | Article |
id | doaj.art-577afe4d18e3446580c272fb4de0893b |
institution | Directory Open Access Journal |
issn | 2164-5515 2164-554X |
language | English |
last_indexed | 2024-03-11T22:00:35Z |
publishDate | 2017-06-01 |
publisher | Taylor & Francis Group |
record_format | Article |
series | Human Vaccines & Immunotherapeutics |
spelling | doaj.art-577afe4d18e3446580c272fb4de0893b2023-09-25T11:02:54ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2017-06-011361466147410.1080/21645515.2017.12814881281488A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infectionYi Yang0Qing Zhu1Weilai Sun2Jingjing Guo3Xiuzhe Ning4Qiao Li5Yan Guo6Junfeng Li7Zhihua Kou8Yusen Zhou9State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and EpidemiologySchool of Laboratory Medicine and Life Science, Wenzhou Medical UniversityState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and EpidemiologyState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and EpidemiologyState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and EpidemiologyState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and EpidemiologyState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and EpidemiologyState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and EpidemiologyState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and EpidemiologySchool of Laboratory Medicine and Life Science, Wenzhou Medical UniversityThe effective protective HIV vaccine should elicit either protective antibodies or effective T cell response, or both. To improve the efficacy of HIV-1 vaccines, HLA polymorphism and HIV-1 diversity are 2 key factors to be considered for vaccine development. In this study, we expressed a recombinant multi-epitope protein MEP1 which has the same amino acid sequence as a DNA vaccine for Chinese population in our previous report. We found that MEP1 alone could elicit moderate levels of humoral and cellular immune responses, but these responses could not provide protection from challenge with a recombinant virus rTTV-lucgag, which expresses Gag of HIV-1 CRF_07BC. Nevertheless, when MEP1 was immunized with aluminum adjuvant, both humoral and cellular immune responses were significantly increased, and they were protective against virus infection; meanwhile, MEP1 with aluminum not only elicited early (10 d post immunization) but also a long-term (at least 44 weeks post immunization) immune responses in BALB/c mice. These results suggested that MEP1 has the potential to be developed as an effective vaccine candidate, and that suitable adjuvant is necessary for this protein to generate protective immune responses.http://dx.doi.org/10.1080/21645515.2017.1281488adjuvantaidsantibodyhiv-1memory immune responsesmulti-epitope proteint cell responses |
spellingShingle | Yi Yang Qing Zhu Weilai Sun Jingjing Guo Xiuzhe Ning Qiao Li Yan Guo Junfeng Li Zhihua Kou Yusen Zhou A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infection Human Vaccines & Immunotherapeutics adjuvant aids antibody hiv-1 memory immune responses multi-epitope protein t cell responses |
title | A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infection |
title_full | A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infection |
title_fullStr | A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infection |
title_full_unstemmed | A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infection |
title_short | A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infection |
title_sort | recombinant multi epitope protein mep1 elicits efficient long term immune responses against hiv 1 infection |
topic | adjuvant aids antibody hiv-1 memory immune responses multi-epitope protein t cell responses |
url | http://dx.doi.org/10.1080/21645515.2017.1281488 |
work_keys_str_mv | AT yiyang arecombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT qingzhu arecombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT weilaisun arecombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT jingjingguo arecombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT xiuzhening arecombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT qiaoli arecombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT yanguo arecombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT junfengli arecombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT zhihuakou arecombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT yusenzhou arecombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT yiyang recombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT qingzhu recombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT weilaisun recombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT jingjingguo recombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT xiuzhening recombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT qiaoli recombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT yanguo recombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT junfengli recombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT zhihuakou recombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection AT yusenzhou recombinantmultiepitopeproteinmep1elicitsefficientlongtermimmuneresponsesagainsthiv1infection |